AVTR · Avantor, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Avantor raised its full-year 2026 organic revenue growth guidance to -0.5% to +0.5% and adjusted EPS guidance to $0.80–$0.83 after Q2 results beat expectations, with VWR returning to positive organic growth and the company repaying $112 million of debt while maintaining a 3.3x adjusted net leverage ratio. However, adjusted EBITDA and segment margins still declined year-over-year on mix and inflationary pressures, and FX is expected to be a headwind in the second half.
- + Raised full-year 2026 organic revenue growth guidance to -0.5% to +0.5% (from -2.5% to -0.5%)
- + Raised full-year 2026 adjusted EPS guidance to $0.80–$0.83 (from $0.77–$0.83)
- + VWR Distribution & Services returned to positive organic revenue growth of 1.7% in Q2
- + Q2 free cash flow of $142.8 million (or $152 million excluding cash restructuring costs) ahead of expectations
- − Total adjusted EBITDA margin declined to 15.0% in Q2 from 16.6% year-over-year
- − FX expected to be a headwind to reported revenue in the second half of 2026
- − GAAP net income fell to $38.1 million in Q2 from $64.7 million in Q2 2025
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVTR
this stock
Avantor, Inc.
|
$10.37B | +31.3% | -3.4% | — | 7.5% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -28.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -17.4% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -8.2% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVTR | +2.0% | +6.0% | +90.0% | +3.5% | +31.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +2.6% | +5.9% | +77.9% | +4.1% | +19.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.